24
Views
10
CrossRef citations to date
0
Altmetric
Original Article

Risk Factors for Neuroleptic-Induced Movement Disorders

, , &
Pages 149-188 | Received 16 Jul 1990, Published online: 07 Jul 2009

References

  • American Psychiatric Association. Diagnostic and statistical manual of mental disorders ed. 3. Washington, DC 1980
  • Ban T. A. Drug treatment in schizophrenia. Canadian Psychiatric Association Journal 1971; 16: 473–485
  • Barbeau A., Porcher E. New data on the genetics of Parkinson's disease. Canadian Journal of Neurological Sciences 1982; 9: 53–66
  • Barnes T. R., Ross M., Trauer T. A comparison of purposeless movements in psychiatric patients treated with antipsychotic drugs, and normal individuals. Journal of Neurology, Neurosurgery and Psychiatry 1983; 46: 540–546
  • Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. Journal of the Neurological Sciences 1973; 20: 415–455
  • Borit A., Rubinstein L. J., Urich H. The striato-nigral degenerations: putaminal pigments and nosology. Brain 1975; 98: 101–112
  • Casey D. Tardive dyskinesia. Psycho-pharmacology: The Third Generation of Progress, H. Y. Meltzer. Raven Press, New York 1987; 1411–1419
  • Crane G. E. Pseudoparkinsonism and tardive dyskinesia. Archives of Neurology 1972; 27: 426–430
  • DeFraites E. G., Davis K. L., Berger P. A. Coexisting tardive dyskinesia and parkinsonism. Biological Psychiatry 1977; 12: 267–272
  • Fann W. E., Lake C. R. The coexistence of parkinsonism and tardive dyskinesia. Diseases of the Nervous System 1974; 35: 324–326
  • Goetz C. G. Drug-induced parkinsonism and idiopathic Parkinson's disease. Archives of Neurology 1983; 40: 325–326
  • Granacher R. P. Differential diagnosis of tardive dyskinesia: An overview. American Journal of Psychiatry 1981; 138: 1288–1297
  • Gureje O. Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 years: relationship to demographic, clinical, treatment, and neuropsychological variables. Journal of Neurology, Neurosurgery and Psychiatry 1988; 51: 1525–1530
  • Gureje O. The significance of subtyping tardive dyskinesia: a study of prevalence and associated factors. Journal of Neurology, Neurosurgery and Psychiatry 1989; 19: 121–128
  • Guttman M., Seeman P. Dopamine D2 receptor density in parkinsonian brain is consonant for duration of disease, age, and duration of L-dopa therapy. Advances in Neurology, M. D. Yahr, K. J. Bergmann. Raven Press, New York 1986; vol. 45: 51–57
  • Hardie R. J., Lees A. J. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. Journal of Neurology, Neurosurgery and Psychiatry 1988; 51: 850–854
  • Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427–442
  • Hoffman W. F., Labs S. M., Casey D. E. Neuroleptic-induced parkinsonism in older schizophrenics. Biological Psychiatry 1987; 22: 427–439
  • Hornykiewicz O. Parkinsonism induced by dopaminergic antagonism. Advances in Neurology, D. B. Calne, T. N. Chase, A. Barbeau. Raven Press, New York 1975; vol. 9: 155–164
  • Hyttel J., Larsen J. J., Christensen A. V., Arnt J. Receptor-binding profiles of neuroleptics. Dyskinesia: research and treatment, D. E. Casey, T. N. Chase, A. V. Christensen, J. Gerlach. Springer Verlag, Berlin 1985; 9–18
  • Kanazawa I. Clinical pathophysiology of basal ganglia disease. Handbook of Neurology: Extrapyramidal Disorders, P. J. Vinken, G. W. Bruyn, H. L. Klawans. Elsevier, Amsterdam 1986; vol. 5: 65–85
  • Kidger T., Barnes T. R. E., Trauer T., Taylor P. J. Subsyndromes of tardive dyskinesia. Psychological Medicine 1980; 10: 513–520
  • Klawans H. L., Rubovits R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. Journal of Neurology, Neurosurgery and Psychiatry 1974; 27: 941–947
  • Klawans H. L. The pharmacology of tardive dyskinesia. American Journal of Psychiatry 1973; 130: 82–86
  • Marsden C. D., Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychological Medicine 1980; 10: 55–72
  • Martin J. P. The Basal Ganglia and Posture. Pitman, London 1967
  • McKenna P. J. Pathology, phenomenology and the dopamine hypothesis of schizophrenia. British Journal of Psychiatry 1987; 151: 288–301
  • Pisa M. Regional specialization of motor functions in the rat striatum: Implications for the treatment of parkinsonism. Progress in Neuropsychopharmacology & Biological Psychiatry 1988; 12: 217–224
  • Rajput A. H., Rozdilsky B., Hornykiewicz O., Shannak K., Lee T., Seeman P. Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Archives of Neurology 1982; 39: 644–646
  • Richardson M. A., Craig T. L. The coexistence of parkinsonism-like symptoms and tardive dyskinesia. American Journal of Psychiatry 1982; 139: 341–343
  • Rosengarten H., Schweitzer J. W., Friedhoff A. J. Induction of oral dyskinesias in naive rats by D, stimulation. Life Sciences 1983; 33: 2479–2482
  • Roy M., Boyer L., Barbeau A. A prospective study of 50 cases of familial Parkinson's disease. Canadian Journal of Neurological Sciences 1983; 10: 37–42
  • Santamaria J., Tolosa E., Valles A. Parkinson's disease with depression: A possible subgroup of idiopathic parkinsonism. Neurology 1986; 36: 1130–1133
  • Schooler N. R., Kane J. M. Research diagnoses for tardive dyskinesia. Archives of General Psychiatry 1982; 39: 486–487
  • Seeman P. Brain dopamine receptors in schizophrenia and tardive dyskinesia. Dyskinesia: research and treatment, D. E. Casey, T. N. Chase, A. V. Christensen, J. Gerlach. Springer Verlag, Berlin 1985; 3–8
  • Simpson G. M., Angus J. W. S. Drug-induced extrapyramidal disorders. Acta Psychiatrica Scandinavica 1970; 212: 1–58, (suppl)
  • Simpson G., Lee J., Zoubok B., Cole J. O., Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology 1979; 64: 171–179
  • Sorokin J. E., Giordani B., Mohs R. C, Losonczy M. F., Davidson M., Siever L. J., Ryan T. A., Davis K. L. Memory impairment in schizophrenic patients with tardive dyskinesia. Biological Psychiatry 1988; 23: 129–135
  • Wagner H. N. Imaging D2 dopamine receptor in Parkinson's disease: A preliminary report. Recent developments in Parkinson's disease, S. Fahn, C. D. Marsden, P. Jenner, P. Teychenne. Raven Press, New York 1986; 115–118
  • Wojcik J. D., Gelenberg A. J., LaBrie R. A. Prevalence of tardive dyskinesia in an outpatient population. Comprehensive Psychiatry 1980; 21: 370–380
  • Zetusky W. J., Jankovic J., Pirrozzolo F. J. The heterogeneity of Parkinson's disease: Clinical and prognostic implications. Neurology 1985; 35: 522–526
  • Aldegunde M., Miquez I., Veira J. Effects of pinealectomy on regional brain serotonin metabolism. International Journal of Neuroscience 1985; 26: 9–13
  • American Psychiatric Association. DSM-III: Diagnostic and Statistical Manual of Mental Disorders3rd ed. APA, Washington, DC 1980
  • Anton-Tay F., Diaz J. L., Fernandez-Guardiola A. On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sciences 1971; 10: 841–850
  • Bitton V., Melamed E. Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy. Journal of Clinical Psychiatry 1984; 45: 28–30
  • Bradbury A. J., Kelly M. E., Smith J. A. Melatonin action in the midbrain can regulate forebrain dopamine function both behaviourally and biochemically. The pineal gland: endocrine aspects, G. M. Brown, S. D. Wain-Wright. Pergamon Press, Oxford 1985; 327–332
  • Casey D. Tardive dyskinesia. Psychopharmacology: The third generation of progress, H. Y. Meltzer. Raven Press, New York 1987; 1411–1419
  • Cotzias G. C, Tang L. C, Miller S. T., Ginos J. Z. Melatonin and abnormal movements induced by L-dopa in mice. Science 1971; 173: 450–452
  • Crane G. E. Pseudoparkinsonism and tardive dyskinesia. Archives of Neurology 1972; 27: 426–430
  • Datta P. G., King M. Melatonin effects on brain and behavior. Neuroscience & Biobehav-ioral Reviews 1980; 4: 451–458
  • DeFraites E. G., Davis K. L., Berger P. A. Coexisting tardive dyskinesia and parkinsonism. Biological Psychiatry 1977; 12: 267–272
  • Dubocovich M. L. Melatonin is a potent modulator of dopamine release in the retina. Nature 1983; 306: 782–784
  • Fahn S., Mayeux R. Unilateral Parkinson's disease and contralateral tardive dyskinesia: A unique case with successful therapy that may explain the pathophysiology of these two disorders. Journal of Neural Transmission 1980; 16: 179–185, (suppl)
  • Fanget F., Claustrat B., Dalery J., Brun J., Terra J. L., Marie-Cardine M., Guyotat J. Nocturnal plasma melatonin levels in schizophrenic patients. Biological Psychiatry 1989; 25: 499–501
  • Fann W. E., Lake C. R. The coexistence of parkinsonism and tardive dyskinesia. Diseases of the Nervous System 1974; 35: 324–326
  • Ferrier I. N., Arendt J., Johnstone E. C., Crow T. J. Reduced nocturnal melatonin secretion in chronic schizophrenia: Relationship to body weight. Clinical Endocrinology 1982; 17: 181–187
  • Fujiwara M., Inagaki C, Miwa S., Takaori S., Saeki Y., Nozaki M. Diurnal variation of dopamine content in the rat pineal gland. Life Sciences 1980; 26: 71–78
  • Gerlach J. Pathophysiological mechanisms underlying tardive dyskinesia. Dyskinesias: research and treatment, D. E. Casey, T. N. Chase, A. V. Christensen, J. Gerlach. Springer Verlag, Berlin 1985; 98–103
  • Godwin-Austen R. B., Lee P. N., Marmot M. G., Stern G. M. Smoking and Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 1982; 45: 577–581
  • Granacher R. P. Differential diagnosis of tardive dyskinesia: An overview. American Journal of Psychiatry 1981; 138: 1288–1297
  • Gureje O. Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 years: Relationship to demographic, clinical, treatment, and neuropsychological variables. Journal of Neurology, Neurosurgery and Psychiatry 1988; 51: 1525–1530
  • Guttman M., Seeman P. Dopamine D2 receptor density in parkinsonian brain is consonant for duration of disease, age, and duration of L-dopa therapy. Advances in neurology, M. D. Yahr, K. I. Bergmann. Raven Press, New York 1986; vol. 45: 51–57
  • Hoffman W. F., Labs S. M., Casey D. E. Neuroleptic induced parkinsonism in older schizophrenics. Biological Psychiatry 1987; 22: 427–439
  • Kanofsky J. D., Sandyk R., Kay S. R. Edentulousness as a risk factor for tardive dyskinesia. Neurology 1990; 40: 146, (suppl)
  • Kay S. R., Fiszbein A., Opler L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987; 13: 261–276
  • Klawans H. L. The pharmacology of tardive dyskinesia. American Journal of Psychiatry 1973; 130: 82–86
  • Koller W. C., Wong G. F., Lang A. Posttraumatic movement disorders: A review. Movement Disorders 1989; 4: 20–36
  • Kopp N., Claustrat B., Tappaz M. Evidence for the presence of melatonin in the human brain. Neuroscience Letters 1980; 19: 237–242
  • Lewinski A., Vaughan M. K., Champney T. H., Reiter R. J., Smith N. K. R. Dark exposure increases the number of pineal concretions in male gerbils (Meriones Unguiculatus). IRCS Medical Science 1983; 11: 977–978
  • Marsden C. D., Jenner P. The pathophysiology of extrapyramidal side effects of neuroleptic drugs. Psychological Medicine 1980; 10: 55–72
  • Miline R. The role of the pineal gland in stress. Journal of Neural Transmission 1980; 47: 191–200
  • Nasrallah H. A., McCalley-Whitters M., Jacoby C. G. Cortical atrophy in schizophrenia and mania: a comparative CT study. Journal of Clinical Psychiatry 1982; 43: 439–441
  • National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). Department of Health, Education, and Welfare, Washington, DC 1974
  • Niles L. P., Wong Y. W., Mishra R. K., Brown G. M. Melatonin receptors in the brain. European Journal of Pharmacology 1979; 55: 219–220
  • Reiter R. J., Welsh M. G., Vaughan M. K. Age-related changes in the intact and sympathetically denervated gerbil pineal gland. American Journal of Anatomy 1976; 146: 427–432
  • Richardson M. A., Craig T. L. The coexistence of parkinsonism-like symptoms and tardive dyskinesia. American Journal of Psychiatry 1982; 139: 341–343
  • Rieder R. O., Mann L. S., Weinberger D. R., vanKammen D. P., Post R. M. Computed tomographic scans in patients with schizophrenia, schizoaffective, and bipolar affective disorder. Archives of General Psychiatry 1983; 41: 602–606
  • Rosengarten H., Schweitzer J. W., Friedhoff A. J. Induction of oral dyskinesias in naive rats by D, stimulation. Life Sciences 1983; 33: 2479–2482
  • Rosenstein R. E., Cardinali D. P. Melatonin increases in vivo GABA accumulation in rat hypothalamus, cerebellum, cerebral cortex and pineal gland. Brain Research 1986; 398: 403–406
  • Sandyk R., Awerbuch G. I., Kay S. R., Kanofsky J. D. Pineal calcification: Marker of tardive dyskinesia. Proceedings and Abstracts of the 143rd Annual Meeting of the American Psychiatric Association, New York, May, 1990; 12–17
  • Sandyk R., Fisher H. The protective role of the pineal gland in tardive dyskinesia. International Journal of Neuroscience 1989a; 43: 215–218
  • Sandyk R., Fisher H. Melatonin mediates the antidyskinetic effects of naloxone in tardive dyskinesia. Journal of Clinical Psyehopharmacology 1989b; 9: 147–148
  • Sandyk R., Fisher H. Increased incidence and severity of neuroleptic-induced movement disorder in pinealectomized rats. International Journal of Neuroscience 1989c; 48: 303–308
  • Sandyk R., Kay S. R. Tardive dyskinesia is associated with positive schizophrenia. International Journal of Neuroscience, (in pressa)
  • Sandyk R., Kay S. R. Negative schizophrenia and the coexistence of parkinsonism and tardive dyskinesia. International Journal of Neuroscience, (in press b)
  • Sandyk R., Kay S. R. Persistent tardive dyskinesia is associated with pineal gland calcification. International Journal of Neuroscience, (in press c)
  • Sandyk R., Kay S. R. Effects of cigarette smoking on cognitive functions and parkinsonism in chronic schizophrenia. Neurology 1990; 40: 424, (suppl)
  • Sandyk R., Mukherjee S. Attenuation of reserpine induced catalepsy by melatonin and the role of the opioid system. International Journal of Neuroscience 1989; 48: 297–301
  • Schooler N. R., Kane J. M. Research diagnoses of tardive dyskinesia. Archives of General Psychiatry 1982; 39: 486–487
  • Seeman P. Brain dopamine receptors in schizophrenia and tardive dyskinesia. Dyskinesia: Research and Treatment, D. E. Casey, T. N. Chase, A. V. Christensen, J. Gerlach. Springer Verlag, Berlin 1985; 3–8
  • Simpson G. M., Angus J. W. S. Drug-induced extrapyramidal disorders. Acta Psychiatrica Scandinavica 1970; 212: 1–58, (suppl)
  • Trentini G. P., De Gaetani C. F., Criscuolo M., Migaldi M., Ferrari G. Pineal calcifications in different physiopathological conditions in humans. Fundamentals and clinics in pineal research, G. P. Trentini, C. DeGaetani, P. Pevet. Raven Press, New York 1987; 291–304
  • Vaughan M. K., Spanel-Borowski K., Karasek M., Champney T. H., Reiter R. J. Action of subcutaneous implants or injections of melatonin on reproductive and metabolic variables and pineal concretions in male gerbils (Meriones unguiculatus). Biomedical Research 1983; 4: 329–336
  • Weinberger D. R. Computed tomography (CT) findings in schizophrenia: Speculations on the meaning of it all. Journal of Psychiatric Research 1984; 18: 477–490
  • Welsh M. G. Pineal calcification: Structural and functional aspects. Pineal Research Reviews 1985; 3: 41–68
  • Wendel O. T., Waterburg L. D., Pearce L. A. Increase in monoamine concentrations in rat brain following melatonin administration. Experientia 1974; 30: 1167–1168
  • Yassa R., Lai S., Korpassy A., Ally J. Nicotine exposure and tardive dyskinesia. Biological Psychiatry 1987; 22: 67–72
  • Yassa R., Mair V. The association of tardive dyskinesia and pseudoparkinsonism. Progress in Neuropsychopharmacology and Biological Psychiatry 1988; 12: 909–914
  • Zisapel N., Laudon M. Dopamine release induced by electrical field stimulation of rat hypothalamus in vitro inhibition by melatonin. Biochemistry, Biophysics Research Communications 1982; 104: 1610–1616
  • American Psychiatric Association. Diagnostic and statistical manual of mental disorders, ed. 3. Washington, DC 1980
  • Anton-Tay F., Diaz J. L., Fernandez-Guardiola A. On the effect of melatonin upon human brain: Its possible therapeutic implications. Life Sciences 1971; 10: 841–850
  • Barbeau A., Pourcher E. Genetics of early onset Parkinson's disease. Current concepts of Parkinson disease and related disorders, M. D. Yahr. Excerpta Medica, Amsterdam 1983
  • Barbeau A. Experience clinique avec le tolbutamide dans la maladie de Parkinson. Union Medicate Cannada 1961; 90: 147–151
  • Bitton V., Melamed E. Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy. Journal of Clinical Psychiatry 1984; 45: 28–30
  • Boyd A. E., Lebovitz H. E., Feldman J. M. Endocrine function and glucose metabolism in patients with Parkinson's disease and their alteration by L-dopa. Journal of Clinical Endocrinology and Metabolism 1971; 33: 829–837
  • Brambilla F., Guastalla A., Guerrini A. Glucose-insulin metabolism in chronic schizophrenia. Diseases of the Nervous System 1976; 37: 98–103
  • Broderick P. A., Jacoby J. H. Serotonergic function in diabetic rats: Psychotherapeutic implications. Biological Psychiatry 1988; 24: 234–239
  • Butterworth R. F., Belanger F., Barbeau A. Hypokinesia produced by antero-lateral hypothalamic 6-hydroxydopamine lesions and its reversal by some antiparkinson drugs. Pharmacology, Biochemistry & Behavior 1977; 8: 41–45
  • Chase T. N. Serotonergic mechanisms in Parkinson's disease. Archives of Neurology 1972; 27: 354–356
  • Cotzias G. C, VanWoert M. H., Schiffer L. M. Aromatic amino acids and modification of parkinsonism. New England Journal of Medicine 1967; 276: 314–319
  • Datta P. C., King M. G. Melatonin: Effects on brain and behavior. Neuroscience and Bio-behavioral Reviews 1978; 4: 451–458
  • Gates E. W., Hyman I. Use of tolbutamide in paralysis agitans: preliminary report. Journal of the American Medical Association 1960; 172: 1351–1354
  • Hansen J. M., Kristensen M. Tolbutamide in the treatment of Parkinson's disease. A double blind trial. Danish Medical Bulletin 1965; 2: 181–184
  • Hassan M. M., Bottoms S. F., Evans M. I. Fetal-alpha-melanocyte-stimulating hormone levels: no correlation with the late fetal growth but increased with diabetes mellitus. American Journal of Obstetrics and Gynecology 1986; 154: 428–430
  • Jacquet Y. F., Abrams G. M. Postural asymmetry and movement disorder after unilateral microinjection of adrenocorticotropin 1–24 in rat brainstem. Science 1982; 218: 175–177
  • Lang A. E., Johnson K. Akathisia in idiopathic Parkinson's disease. Neurology 1987; 37: 477–481
  • Lipman I. J., Boykin M. E., Flora R. E. Glucose intolerance in Parkinson's disease. Journal of Chronic Diseases 1974; 27: 573–579
  • Lozovsky D., Sailer C. F., Kopin I. J. Dopamine receptor binding is increased in diabetic rats. Science 1981; 214: 1031–1033
  • Mukherjee S., Bilder R. M., Sackeim H. L. Tardive dyskinesia and glucose metabolism. Archives of General Psychiatry 1986; 43: 193
  • National Institute of Mental Health. Abnormal involuntary movement scale. Department of Health, Education, and Welfare, Alcohol, Drug Abuse and Mental Health Administration, Washington, DC 1964
  • Pang S. F., Tang F., Tang P. L. Alloxan-induced diabetes and the pineal gland: Differential effects on the levels of pineal N-acetylserotonin, pineal melatonin, and serum melatonin. Journal of Pineal Research 1985; 2: 79–85
  • Pique L., Jegou S., Bertagna X., Javoy-Agid F., Seurin D., Proeschel M. F., Girard F., Agid Y., Vaudry H., Luton I. P. Pro-opiomelanocortin peptides in the human hypothalamus: Comparative studies between normal subjects and Parkinson patients. Neuroscience Letters 1985; 54: 141–146
  • Podolsky S., Leopold N. A., Sax D. S. Increased frequency of diabetes mellitus in patients with Huntington's chorea. Lancet 1972; 1: 1356–1359
  • Rainero I., Kaye J. A., May C, Durso R., Katz D. I., Albert M. L., Wolfe N., Pinessi L., Friedland R. P., Rapoport S. I. Alpha-melanocyte stimulating hormonelike immuno-reactivity is increased in cerebrospinal fluid of patients with Parkinson's disease. Archives of Neurology 1988; 45: 1224–1227
  • Richardson M. A., Craig T. J. The coexistence of Parkinsonism-like symptoms and tardive dyskinesia. American Journal of Psychiatry 1982; 139: 341–343
  • Sailer C. F., Chiodo L. A. Glucose suppresses basal firing and haloperidol-induced increases in firing rate of central dopaminergic neurons. Science 1980; 210: 1269–1271
  • Sandyk R. The effects of dopamine hydrochloride on insulin action in isolated rat adipocytes. M.Sc. Dissertation, University of the Witwatersrand, JohannesburgSouth Africa 1984
  • Singh S., Sandyk R., Kay S. R. Diabetes mellitus as a risk factor for neuroleptic-induced akathisia. Neurology 1990; 40: 146, (suppl)
  • Szabo A. J., Szabo O. Influence of the insulin sensitive CNS regulator receptor on hepatic glucose metabolism. Journal of Physiology 1975; 253: 121–133
  • Szabo O., Szabo A. J. Effects of autonomic neurotransmitter and inhibitor drugs on the insulin sensitive CNS glucoregulatory center. Diabetes 1974; 23: 342
  • Tolosa E. S., Santamaria J. Parkinsonism and basal ganglia infarcts. Neurology 1984; 34: 1516–1518
  • VanWoert M. H., Mueller P. S. Glucose, insulin, and free fatty acid metabolism in Parkinson's disease treated with levodopa. Clinical Pharmacology & Therapeutics 1971; 12: 360–367
  • Wilkinson D. G. Psychiatric aspects of diabetes mellitus. British Journal of Psychiatry 1981; 138: 1–9
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders ed. 3. Washington, DC 1980
  • Ayd F. J. A survey of drug-induced extrapyramidal reactions. Journal of the American Medical Association 1961; 175: 1054–1060
  • Goetz C. G. Drug-induced parkinsonism and idiopathic Parkinson's disease. Archives of Neurology 1983; 40: 325–326
  • Hardie R. J., Lees A. J. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. Journal of Neurology, Neurosurgery and Psychiatry 1988; 51: 850–854
  • Hausner R. S. Neuroleptic-induced parkinsonism and Parkinson's disease: differential diagnosis and treatment. Journal of Clinical Psychiatry 1983; 44: 13–16
  • Johnson D. A. W. Prevalence and treatment of drug-induced extrapyramidal symptoms. British Journal of Psychiatry 1978; 132: 27–30
  • Korczyn A. D., Inzelberg R., Treves T., Neufeld M., Reider I., Rabey P. M. Dementia of Parkinson's disease. Advances in Neurology, M. D. Yahr, K. J. Bergmann. Raven Press, New York 1986; vol. 45: 399–403
  • Langston J. W., Forno L. S. The hypothalamus in Parkinson disease. Annals of Neurology 1978; 3: 129–133
  • Lipman I. J., Boykin M. E., Flora R. E. Glucose intolerance in Parkinson's disease. Journal of Chronic Disease 1974; 27: 537–579
  • Marsden C. D., Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychological Medicine 1980; 10: 55–72
  • Mindham R. H. S., Ahmed S. W. A., Clough C. G. A controlled study of dementia in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 1982; 45: 969–974
  • Mukherjee S., Bilder R. M., Sackheim H. A. Tardive dyskinesia and glucose metabolism. Archives of General Psychiatry 1986; 43: 193
  • Mutch W. J., Dingwall-Fordyce I., Downie A. W., Paterson J. G., Roy S. K. Parkinson's disease in a Scottish city. British Medical Journal 1986; 292: 534–536
  • National Institute of Mental Health. Abnormal Involuntary Movement Scale. Department of Health, Education, and Welfare, Alcohol, Drug Abuse and Mental Health Administration, Washington, DC 1964
  • Rajput A. H., Rozdilsky B., Hornykiewicz O., Shannak K., Lee T., Seeman P. Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Archives of Neurology 1982; 39: 644–646
  • Stephen P. J., Williamson J. Drug-induced Parkinsonism in the elderly. Lancet 1984; 2: 1082–1083
  • Waddington J. L., Youssef H. A. An unusual cluster of tardive dyskinesia in schizophrenic: Association with cognitive dysfunction and negative symptoms. American Journal of Psychiatry 1986; 143: 1162–1165
  • Wilkinson D. G. Psychiatric aspects of diabetes mellitus. British Journal of Psychiatry 1981; 138: 1–9
  • Yaryura-Tobias J. A., Wolpert A., Dana L., Merlis S. Action of L-dopa in drug induced extrapyramidalism. Diseases of the nervous system 1970; 31: 60–63
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders ed. 3. Washington, DC 1980
  • Ayd F. J. A survey of drug-induced extrapyramidal reactions. Journal of the American Medical Association 1961; 175: 1054–1060
  • Braude W. M., Barnes T. R. E. Late onset akathisia–an indicant of covert dyskinesia: two case reports. American Journal of Psychiatry 1983; 140: 611–612
  • Gibb W. R. G., Lees A. J. The clinical phenomenon of akathisia. Journal of Neurology, Neurosurgery and Psychiatry 1986; 49: 861–866
  • Karam J. H. Diabetes mellitus, hypoglycemia and lipoprotein disorders. Current medical diagnosis & treatment, S. A. Schroeder, M. A. Krupp, L. M. Tierney, S. J. McPhee. Appleton & Lange, Nor-walk 1989; 789
  • Klawans H. L. The pharmacology of tardive dyskinesia. American Journal of Psychiatry 1973; 130: 82–86
  • Lackovic Z., Salkovic M., Kuqi Z., Relja M. Dopamine, norepinephrine and serotonin in the brain of diabetic rat and man. Journal of Neurochemistry 1985; 44: S94, (suppl)
  • Lees A. J. Tics and related disorders. Churchill-Livinstone, Edinburgh 1985
  • Lozovsky D., Sailer C. F., Kopin I. J. Dopamine receptor binding is increased in diabetic rats. Science 1981; 214: 1031–1033
  • Mukherjee S., Bilder R. M., Sackheim H. A. Tardive dyskinesia and glucose metabolism. Archives of General Psychiatry 1986; 43: 193
  • Mukherjee S., Roth S. D., Sandyk R., Schnur D. B. Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance. Psychiatry Research 1989; 29: 17–27
  • National Institute of Mental Health. Abnormal Involuntary Movement Scale. Department of Health, Education, and Welfare, Alcohol, Drug Abuse and Mental Health Administration, Washington, DC 1964
  • Sailer C. F., Chiodo L. A. Glucose suppresses basla firing and haloperidol-induced increases in firing rate of central dopaminergic neurons. Science 1980; 210: 1269–1271
  • Sandyk R. Increased incidence of neuroleptic-induced perioral movements in the rat by hyperglycemia. International Journal of Neuroscience 1990; 50: 227–232
  • VanPutten T., May P., Marder S. R. Akathisia with haloperidol and thiothixene. Archives of General Psychiatry 1984; 41: 1036–1039
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders ed. 3. Washington, DC 1980
  • Ayd F. J. A survey of drug-induced extrapyramidal reactions. Journal of the American Medical Association 1961; 175: 1054–1060
  • Cash R., Dennis T., L'Heureux R., Raisman R., Javoy-Agid F., Scatton B. Parkinson's disease and dementia: Norepinephrine and dopamine in locus coeruleus. Neurology 1987; 37: 42–46
  • Davis J. M. Comparative doses and costs of antipsychotic medication. Archives of General Psychiatry 1976; 33: 858–861
  • Famuyiwa O. O., Eccleston D., Donaldson A. A., Garside R. F. Tardive dyskinesia and dementia. British Journal of Psychiatry 1979; 135: 500–504
  • Goetz C. G. Drug-induced parkinsonism and idiopathic Parkinson's disease. Archives of Neurology 1983; 40: 325–326
  • Gottfries C. G., Gottfries I., Roos B. E. The investigation of homovanillic acid in human brain and its correlation to senile dementia. British Journal of Psychiatry 1969; 115: 563–574
  • Hardie R. J., Lees A. J. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. Journal of Neurology, Neurosurgery and Psychiatry 1988; 51: 850–854
  • Hoffman W. F., Labs S., Casey D. E. Neuroleptic-induced Parkinsonism in older schizophrenics. Biological Psychiatry 1987; 22: 427–439
  • Holden J. M.C, Itil T. M., Keskiner A. The treatment of lobotomized schizophrenic patients with butaperazine. Current Therapeutic Research 1969; 11: 418–428
  • Hornykiewicz O. Brain neurotramsitter changes in Parkinson's disease. Movement disorders, C. D. Marsden, S. Fahn. Butterworth, Woburn Mass 1982; 41–58
  • Luchins D. J., Jackman H., Meltzer H. Y. Lateral ventricular size and drug-induced parkinsonism. Psychiatry Research 1983; 9: 9–16
  • Mann D. M. A., Yates P. O., Hawkes J. The pathology of the human locus coeruleus. Clinical Neuropathology 1983; 2: 1–7
  • McLelland H. A. Discussion on assessment of drug-induced extrapyramidal reactions. British Journal of Clinical Pharmacology 1976; 401–403, suppl
  • Mindham R. H. S. Assessment of drug-induced extrapyramidal reactions and of drugs given for their control. British Journal of Clinical Pharmacology 1976; 395–400, suppl
  • Molsa P. K., Marttila R. J., Rinne U. K. Extrapyramidal signs in Alzheimer's disease. Neurology 1984; 34: 1114–1116
  • Morris J. C, Drazner M., Grant E. A., Goldring J. Clinical and pathological aspects of parkinsonism in Alzheimer's disease. A role for extranigral factors?. Archives of Neurology 1989; 46: 651–657
  • Mortimer J. A., Pirozzolo F. J., Hansen E. C., Webster D. D. Relationship of motor symptoms to intellectual deficits in Parkinson's disease. Neurology 1982; 32: 133–37
  • Pearce J. The extrapyramidal disorder of Alzheimer's disease. European Neurology 1974; 12: 94–103
  • Perry E. K., Tomlinson B. E., Blessed G., Perry R. H., Cross A. J., Crow T. T. Neuropathological and biochemical observations on the noradrenergic system in Alzheimer's disease. Journal of the Neurological Sciences 1981; 51: 279–287
  • Rajput A. H., Rozdilsky B., Hornykiewicz O., Shannak K., Lee T., Seeman P. Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Archives of Neurology 1982; 39: 644–646
  • Richardson M. A., Craig T. J. The coexistence of parkinsonism-like symptoms and tardive dyskinesia. American Journal of Psychiatry 1982; 139: 341–343
  • Sandyk R., Iacono R. P. The relationship of the reticular system to the primary pathoetiology of Parkinson's disease. International Journal of Neuroscience 1988; 42: 297–300
  • Sandyk R., Kay S. R. Coexistence of drug-induced parkinsonism and tardive dyskinesia. International Journal of Neuroscience, (in press)
  • Simpson G. M., Angus J. W. S. Drug-induced extrapyramidal disorders. Acta Psychiatrica Scandinavica 1970; 212: 1–58, (suppl)
  • Stern Y., Mayeux R., Cote L. Reaction time and vigilance in Parkinson's disease. Possible role of altered norpeinephrine metabolism. Archives of Neurology 1984; 41: 1086–1089
  • Sulkava R. Alzheimer's disease and senile dementia of Alzheimer's type: a comparative study. Acta Neurologica Scandinavica 1982; 65: 636–650
  • Waddington J. L., Youssef H. A. An unusual cluster of tardive dyskinesia in schizophrenic: Association with cognitive dysfunction and negative symptoms. American Journal of Psychiatry 1986; 143: 1162–1165
  • Winblad B., Adolfsson R., Carlsson A. Biogenic amines in brains of patients with Alzheimer's disease. Alzheimer's disease: A report of progress in research, S. Corkin, K. L. Davis, J. H. Crowdon. Raven Press, New York 1982; 25–33
  • Youssef H. A., Waddington J. L. Primitive (developmental) reflexes and diffuse cerebral dysfunction in schizophrenia and bipolar affective disorder: Overrepresentation in patients with tardive dyskinesia. Biological Psychiatry 1988; 23: 791–796
  • Zetusky W. J., Jankovic J., Pirozzolo F. J. The heterogeneity of Parkinson's disease: Clinical and prognotic implications. Neurology 1985; 35: 522–526
  • Adler L. A., Angrist B., Reiter S., Rotrosen J. Neuroleptic-induced akathisia: a review. Psychopharmacology 1989; 97: 1–11
  • American Psychiatric Association. A psychiatric glossary 5th ed. APA, Washington, DC 1980a
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders ed. 3. Washington, DC 1980b
  • Asberg M., Traskman L., Thoren P. 5-HIAA in the cerebrospinal fluid: a biochemical suicide predictor?. Archives of General Psychiatry 1976; 33: 1193–1197
  • Ayd F. J. A survey of drug-induced extrapyramidal reactions. Journal of the American Medical Association 1961; 175: 1054–1060
  • Bing R. Ueber einige Bemerkenswerte Begleiterscheinungen der extrapyramidalen Rigiditat (Akathesie-Mikrographie-Kinesia paradoxica). Schweizerische Medizinische Wochenschrift 1923; 53: 167–171
  • Braude W. M., Barnes T. R. E., Gore S. M. Clinical characteristics of akathisia: A systematic investigation of acute psychiatric inpatient admissions. British Journal of Psychiatry 1983; 143: 139–150
  • Curzon G. Serotonergic mechanisms in depression. Clinical Neuropharmacology 1988; 11: S11–S20, (suppl 2)
  • Drake R. E., Ehrlich J. Suicide attempts associated with akathisia. American Journal of Psychiatry 1985; 142: 499–501
  • Gibb W. R. G., Lees A. J. The clinical phenomenon of akathisia. Journal of Neurology, Neurosurgery and Psychiatry 1986; 49: 861–866
  • Haskovec L. Nouvelles remarques sur ľakathisie. Nouvelle Iconograph Salpetriere 1903; 16: 287–296
  • Kalinowsky L. B. Appraisal of the “tranquilizers” and their influence on other somatic treatments in psychiatry. American Journal of Psychiatry 1958; 115: 294–300
  • Keckich W. A. Neuroleptic: Violence as a manifestation of akathisia. Journal of the American Medical Association 1978; 240: 2185
  • Kendler K. S. A medical student's experience with akathisia. American Journal of Psychiatry 1976; 133: 454–455
  • Lang A. E., Johnson K. Akathisia in idiopathic Parkinson's disease. Neurology 1987; 37: 411–481
  • Lees A. J. Tics and related disorders. Churchill-Livingstone, Edinburgh 1985
  • Marsden C. D., Jenner P. The pathophysiology of extrapryamidal side effects of neuroleptic drugs. Psychological Medicine 1980; 10: 55–72
  • Muehlbauer H. D. Human aggression and the role of central serotonin. Pharmacopsychiatrie 1985; 18: 218–221
  • Mukherjee S., Rosen A. M., Cardenas C, Varia V., Olarte S. Tardive dyskinesia in psychiatric outpatients. Archives of General Psychiatry 1982; 39: 466–469
  • Ninan P. T., vanKammen D. P., Scheinin M., Linnoila M., Bunney W. E., Goodwin F. K. CSF 5-hydroxyindoleacetic acid levels in suicidal schizophrenic patients. American Journal of Psychiatry 1984; 141: 566–569
  • Roy A., DeJong J., Linnoila M. Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients. A 5-year follow-up study. Archives of General Psychiatry 1989; 46: 609–612
  • Sandyk R. Neuroleptic-induced akathisia: A role for MSH peptides. Psychopharmacology 1989; 99: 134–135
  • Shaw E. D., Mann J. J., Widen P., Sinsheimer L. M., Brunn R. D. A case of suicidal and homicidal ideation aned akathisia in a double-blind neuroleptic crossover study. Journal of Psychopharmacology 1986; 6: 196–197
  • Shen W. W. Akathisia: An overlooked, distressing, but treatable condition. The Journal of Nervous and Mental Disease 1981; 169: 599–600
  • Simpson G. M., Angus J. W. S. Drug-induced extrapyramidal disorders. Acta Psychiatrica Scandinavica 1970; 212: 1–58, (suppl)
  • Stewart J. Akathisia following traumatic brain injury: treatment with bromocriptine. Journal of Neurology, Neurosurgery and Psychiatry 1989; 52: 1200–1201
  • vanPraag H. M. Neurotransmitters and CNS disease: Depression. Lancet 1982; 2: 1259–1264
  • vanPraag H. M. CSF-5HIAA and suicide in non-depressed schizophrenics. Lancet 1983; 1: 977–978
  • vanPutten T. Why do schizophrenic patients refuse to take their drugs?. Archives of General Psychiatry 1974; 31: 67–72
  • vanPutten T. The many faces of akathisia. Comprehensive Psychiatry 1975; 16: 43–47
  • vanPutten T., May P., Marder S. R. Akathisia with haloperidol and thiothixene. Archives of General Psychiatry 1984; 41: 1036–1039
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders ed. 3. Washington, DC 1980
  • Ayd F. J. A survey of drug-induced extrapyramidal reactions. Journal of the American Medical Association 1961; 175: 1054–1060
  • Ban T. A. Drug treatment in schizophrenia. Canadian Psychiatric Association Journal 1971; 16: 473–485
  • Donlon P. T., Stenson R. L. Neuroleptic-induced extrapyramidal symptoms. Diseases of the Nervous System 1976; 37: 629–635
  • Hoffman W. F., Labs S. M., Casey D. E. Neuroleptic-induced parkinsonism in older schizophrenics. Biological Psychiatry 1987; 22: 427–439
  • Kane J. M., Woerner M., Liberman J. Tardive dyskinesia: Prevalence, incidence, and risk factors. Dyskinesia: research and treatment, D. E. Casey, T. N. Chase, A. V. Christensen, J. Gerlach. Springer Verlag, Berlin 1985; 72–78
  • Kane J. M., Woerner M., Lieberman J. Tardive dyskinesia: Prevalence, incidence and risk factors. Journal of Clinical Psychopharmacology 1988; 8: 52S–56S, (suppl)
  • Marsden C. D., Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drug. Psychological Medicine 1980; 10: 55–72
  • Mukherjee S., Rosen A. M., Caracci G., Shukla S. Persistent tardive dyskinesia in bipolar patients. Archives of General Psychiatry 1986; 43: 342–346
  • Rupniak N. M. J., Jenner P., Marsden C. D. Acute dystonia induced by neuroleptic drugs. Psychopharmacology 1986; 88: 403–419
  • Schooler N. R., Kane J. M. Research diagnoses for tardive dyskinesia. Archives of General Psychiatry 1982; 39: 486–487
  • Simpson G. M., Angus J. W. S. Drug-induced extrapyramidal disorders. Acta Psychiatrica Scandinavica 1970; 212: 1–58, (suppl)
  • Youssef H. A., Waddington J. L. Primitive (developmental) reflexes and diffuse cerebral dysfunction in schizophrenia and bipolar affective disorder: Overrepresentation in patients with tardive dykinesia. Biological Psychiatry 1988; 23: 791–796
  • Adams R. D., Victor M. Principles of neurology. McGraw-Hill, San Francisco 1977; 717–719
  • Alcolado J. C, Moore I. E., Weller R. O. Calcifications in the human choroid plexus, menigiomas and pineal gland. Neuropathology and Applied Neurobiology 1986; 12: 235–250
  • Ashcroft G. W., Dow R. C, Moir A. T. B. The active transport of 5-hydroxyindoleacetic acid and 3-methoxy-4 hydroxyphenylacetic acid from a recirculatory perfusion system of the cerebral ventricles of the unanaethetized dog. Journal of Physiology 1968; 199: 397–425
  • Campbell W. G., Raskind M. A., Gordon T., Mei Shaw C. Iron pigment in the brain of a man with tardive dyskinesia. American Journal of Psychiatry 1985; 142: 364–365
  • Casey D. E., Denney D. Pharmocological characterisation of tardive dyskinesia. Psycho-pharmacology 1977; 54: 1–9
  • Chase T. N., Schnur J. A., Gordon E. K. Cerebrospinal fluid monoamine catabolites in drug-induced extrapyramidal disorders. Neuropharmacology 1970; 9: 265–268
  • Decker J. F., Quay W. B. Stimulatory effects of melatonin on ependymal epithelium of choroid plexus in golden hamsters. Journal of Neural Transmission 1982; 55: 53–67
  • Friedheim E., Corvi C, Graziano J., Donnelli T., Breslin D. Choroid plexus as protective sink for heavy metals. Lancet 1983; 1: 981–982
  • Gureje O. Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 years: relationship to demographic, clinical, treatment, and neuropsychological variables. Journal of Neurology, Neurosurgery and Psychiatry 1988; 51: 1525–1530
  • Gureje O. The significance of subtyping tardive dyskinesia: a study of prevalence and associated factors. Psychological Medicine 1989; 19: 121–128
  • Hunter R., Blackwood W., Smith M. C. Neuropatholgical findings in three cases of persistent dyskinesia following phenothiazine medication. Journal of the Neurological Sciences 1968; 7: 763–773
  • Kidger T., Barnes T. R. E., Trauer T., Taylor P. J. Subsyndromes of tardive dyskinesia. Psychological Medicine 1980; 10: 513–520
  • Korsgaard O., Gerlach J., Christensson E. Behavioral aspects of serotonin-dopamine interaction in the monkey. European Journal of Pharmacology 1985; 118: 245–252
  • Lidvall M., Owman C. Autonomic nerves in the mammalian choroid plexus and their influence on the formation of cerebrospinal fluid. Journal of Cerebral Blood Flow and Metabolism 1981; 1: 245–266
  • MacPherson P., Matheson M. S. Comparison of calcification of pineal, habenular commisure and choroid plexus on plain films and computed tomography. Neuroradiology 1979; 18: 67–72
  • Manton W. I., Kirkpatrick J. B., Cook J. D. Does the choroid plexus really protect the brain from lead?. Lancet 1984; 2: 351
  • Maurizi C. P. The pathophysiology of enlarged ventricles in normal pressure communicating hydrocephalus and schizophrenia: A possible therapeutic role for melatonin. Medical Hypotheses 1987; 23: 61–66
  • Modic M. T., Weinstein M. A., Rothner D., Evenberg G., Duchesneau P. M., Kaufman B. Calcification of the choroid plexus visualized by computed tomography. Neuroradiology 1980; 135: 369–372
  • Moskowitz M. A., Liebmann J. E., Reinhard J. F., Schlosberg A. Raphe origin of serotonin-containing neurons within the choroid plexus of the rat. Brain Research 1979; 169: 590–594
  • Owens D. G.C, Johnstone E. C, Crow T. J., Frith C. D., Jagoe J. R., Kreel L. Lateral ventricular size in schizophrenia: relationship to the disease process and its clinical manifestations. Psychological Medicine 1985; 15: 27–41
  • Pfefferbaum A., Zipursky R. B., Lim K. O., Zatz L. M., Stahl S. M., Jernigan T. L. Computed tomographic evidence for generalized sulcal and ventricular enlargement in schizophrenia. Archives of General Psychiatry 1988; 45: 633–640
  • Potkin S. G., Weinberger D. R, Linnoila M., Wyatt R. J. Low CSF 5-hydroxyindoleacettic acid in schizophrenic patients with enlarged cerebral ventricles. American Journal of Psychiatry 1983; 140: 21–25
  • Rapoport S. I. Blood-brain barrier in physiology and medicine. Raven Press, New York 1976; 43–86
  • Rudin D. O. Covert transport dysfunction in the choroid plexus as a possible cause of schizophrenia. Schizophrenia Bulletin 1979; 5: 623–626
  • Rudman D., Hollins B. M., Lewis N. C., Scott J. W. Effects of hormones on 3′5,-cyclic adenosine monophosphate in choroid plexus. American Journal of Physiology 1977; 232: 353–357
  • Sandyk R., Awerbuch G. I., Kay S. R. Pineal calcification and tardive dyskinesia. Lancet 1990; 335: 1528
  • Simpson G., Lee J., Zoubok B., Cole J. O., Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology 1979; 64: 171–179
  • Smith J. M., Baldessarini R. J. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Archives of General Psychiatry 1980; 37: 1368–1373
  • Smulders A. P., Wright E. M. Role of choroid plexus in transport of melatonin between blood and brain. Brain Research 1980; 191: 555–558
  • Tapp E. The histology and pathology of the human pineal gland. Progress in Brain Research 1979; 52: 481–500
  • Zimmerman R. A., Bilaniuk L. T. Age-related incidence of pineal calcification detected by computed tomography. Neuroradiology 1982; 142: 659–662

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.